Abstract
Traveler's diarrhea remains a common health problem among individuals from industrialized nations who travel to developing nations. The syndrome is self-limited and not incapacitating for the majority of sufferers. It affects all age groups with variable frequency and may manifest more severely in the very young. In certain geographic areas, enterotoxigenic Escherichia coli and Salmonella infections occur more frequently in the summer months whereas Campylobacter is more frequently identified in winter months. When antimicrobial therapy is indicated, the combination of a quinolone and an antimotility agent appears to be safe and effective in decreasing the duration of illness. A nonabsorbable oral monobactam has proven to be safe and effective and may, in the future, be useful in children and in pregnancy. The development of effective oral vaccines, which have proven moderately successful in field trials, offers hope for an alternative modality in the prevention of traveler's diarrhea.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
